Exploring the molecular mechanism of glycyrrhetinic acid in the treatment of gastric cancer based on network pharmacology and experimental validation
Open Access
- 11 May 2023
- journal article
- research article
- Published by Impact Journals, LLC in Aging
- Vol. 15 (9) , 3839-3856
Abstract
There is a wide range of pharmacological effects for glycyrrhetinic acid (GRA). Previous studies have shown that GRA could inhibit the proliferation of tumor cells, showing a promising value in the treatment of gastric cancer (GC). Nonetheless, the precise mechanism of the effect of GRA on GC remains unclear. We explored cellular and molecular mechanisms of GRA based on network pharmacology and in vitro experimental validation. In this study, we predicted 156 potential therapeutic targets for GC with GRA from public databases. We then screened the hub targets using protein-protein interaction network (PPI) and conducted clinical correlation analysis. Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment showed that GRA made anti-GC effects through multiple targets and pathways, particularly the MAPK signaling pathway. Next, molecular docking results revealed a potential interaction between GRA and MAPK3. In addition, qRT-PCR experiments revealed that 18β-GRA was able to suppress mRNA expression of KRAS, ERK1 and ERK2 in AGS cells. Western blotting results also revealed that 18β-GRA was able to suppress the expression of KRAS and p-ERK1/2 proteins in AGS cells. Additionally, immunofluorescence assays revealed that 18β-GRA inhibited p-ERK1/2 nuclear translocation in AGS cells. These results systematically reveal that 18β-GRA may have anti-tumor effects on GC by modulating the MAPK signaling pathway.Keywords
This publication has 39 references indexed in Scilit:
- Synthesis and Anticancer Activities of Glycyrrhetinic Acid DerivativesMolecules, 2016
- Rapid determination of flavonoids in licorice and comparison of three licorice speciesJournal of Separation Science, 2016
- Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapyOncogene, 2015
- Targeting RAS–ERK signalling in cancer: promises and challengesNature Reviews Drug Discovery, 2014
- Design, Synthesis and In Vitro Evaluation of 18β-Glycyrrhetinic Acid Derivatives for Anticancer Activity Against Human Breast Cancer Cell Line MCF-7Current Medicinal Chemistry, 2014
- Triterpene Functional Genomics in Licorice for Identification of CYP72A154 Involved in the Biosynthesis of GlycyrrhizinThe Plant Cell, 2011
- Apoptosis and cancer: the genesis of a research fieldNature Reviews Cancer, 2009
- Apoptosis: A Review of Programmed Cell DeathToxicologic Pathology, 2007
- Mxi2 promotes stimulus‐independent ERK nuclear translocationThe EMBO Journal, 2007
- Increased MAPK Activity and MKP-1 Overexpression in Human Gastric AdenocarcinomaBiochemical and Biophysical Research Communications, 1998